North America Cervical Cancer Diagnostics and Therapeutics Market

North America Cervical Cancer Diagnostics and Therapeutics Market Size (2024 to 2029)

The Cervical Cancer Diagnostics and Therapeutics Market size in North America is estimated to value USD 1732.49 million by 2029 from USD 1430.85 million in 2024, growing at a CAGR of 3.90% during the forecast period.  

The growth of the cervical cancer diagnostics and therapies market in North America is majorly driven by government initiatives supporting cervical cancer prevention, increasing prevalence of cervical cancer, raising awareness increased to early diagnosis, and strong R&D key players.

According to the World Health Organization (WHO), more than 270,500 women die from cervical cancer each year. The death rate from cervical cancer is higher in developing regions due to inadequate detection in the early stages of the disease. With the increasing adoption of cervical cancer diagnostic tests to detect cervical cancer, the market is expected to grow.

Increased awareness of the general population about the care, prevention, and treatment of cervical cancer, increased behaviors, such as sex with multiple partners and smoking, certain genetic factors, and a weakened immune system are linked to the growth of cervical cancer diagnostic and therapeutic market. In addition, factors such as the increasing prevalence of Human Papilloma Virus (HPV) infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are driving the market growth.

For example, In the US, a government's popular insurance program, Medicare, covers the Pap test, pelvic exam, and clinical breast exam for cervical cancer screening every two years. These programs have proven to be responsible for the growth of the overall market.

HPV home testing kits help women easily collect samples and get results independently without having to go to the lab for testing. Hence, companies are focusing on patient comfort, thereby providing better market growth opportunities in the region.

A clear lack of trained health professionals and a lack of awareness among the people to help achieve effective implementation of screening programs is expected to restrain the growth of the Cervical Cancer Diagnostics and Therapeutics Market in North America growth. In addition, the economic and social constraints in this region will be a major challenge for the major market players seeking to invest in this region, potentially hampering the growth of the North American cervical cancer diagnosis and therapeutics market.

This research report on the North America Cervical Cancer Diagnostics and Therapeutics Market is segmented and sub-segmented into the following categories.

By Diagnostics Test:

• Pap Smear Test
• HPV Testing
• Colposcopy
• Cervical Cancer Biopsy

By Methods:

• Molecular Method
• Cytopathological Method
• Physical Method

By Therapies:

• Surgery
• Radiation Therapy
• Chemotherapy
• Others

By End-users:

• Hospitals
• Laboratories
• Independent Physicians
• Clinics
• Others

By Country:

• United States
• Canada
• Rest of North America

Geographically, the large market share of the North American market was accounted for by the U.S. in 2020, and this can be attributed to the strong awareness of disease prevention among women in the region, as well as the many initiatives put in place to prevent cervical cancer, which has broadened the reach of insurance coverage for cervical screening, especially for people with low-income women.

The United States government contributes to the coverage and reimbursement of smears. The federal law was passed through the Affordable Care Act (ACA) to require coverage for cervical cancer screenings. Self-insurance plans also cover it.

There are also support programs like the National Cervical Cancer Early Detection and Program (NBCCEDP), which offers cervical cancer screenings to uninsured women free or at a meager cost. In addition, according to the Federal Advisory Committee on Immunization Practices (ACIP) recommendations, the U.S. government is attempting to include the HPV vaccine in insurance plans and include it in the Federal Childhood Immunization Program (VFC). All of these government initiatives for cervical cancer prevention have resulted in market growth.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America Cervical Cancer Diagnostics and Therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare, Volition Rx.